Literature DB >> 10067874

The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins.

B L Wagner1, G Pollio, P Giangrande, J C Webster, M Breslin, D E Mais, C E Cook, W V Vedeckis, J A Cidlowski, D P McDonnell.   

Abstract

We have identified two novel compounds (RTI 3021-012 and RTI 3021-022) that demonstrate similar affinities for human progesterone receptor (PR) and display equivalent antiprogestenic activity. As with most antiprogestins, such as RU486, RTI 3021-012, and RTI 3021-022 also bind to the glucocorticoid receptor (GR) with high affinity. Unexpectedly, when compared with RU486, the RTI antagonists manifest significantly less GR antagonist activity. This finding indicates that, with respect to antiglucocorticoid function, receptor binding affinity is not a good predictor of biological activity. We have determined that the lack of a clear correlation between the GR binding affinity of the RTI compounds and their antagonist activity reflects the unique manner in which they modulate GR signaling. Previously, we proposed a two step "active inhibition" model to explain steroid receptor antagonism: 1) competitive inhibition of agonist binding; and 2) competition of the antagonist bound receptor with that activated by agonists for DNA response elements within target gene promoters. Accordingly, we observed that RU486, RTI 3021-012, and RTI 3021-022, when assayed for PR antagonist activity, accomplished both of these steps. Thus, all three compounds are "active antagonists" of PR function. When assayed on GR, however, RU486 alone functioned as an active antagonist. RTI 3021-012 and RTI 3021-022, on the other hand, functioned solely as "competitive antagonists" since they were capable of high affinity GR binding, but the resulting ligand receptor complex was unable to bind DNA. These results have important pharmaceutical implications supporting the use of mechanism based approaches to identify nuclear receptor modulators. Of equal importance, RTI 3021-012 and RTI 3021-022 are two new antiprogestins that may have clinical utility and are likely to be useful as research reagents with which to separate the effects of antiprogestins and antiglucocorticoids in physiological systems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067874     DOI: 10.1210/endo.140.3.6581

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active.

Authors:  Laura J Lewis-Tuffin; Christine M Jewell; Rachelle J Bienstock; Jennifer B Collins; John A Cidlowski
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

2.  Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters.

Authors:  C M Pariante; A Makoff; S Lovestone; S Feroli; A Heyden; A H Miller; R W Kerwin
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 3.  Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer.

Authors:  Sergio C Chai; William C Wright; Taosheng Chen
Journal:  Med Res Rev       Date:  2019-11-28       Impact factor: 12.944

4.  The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.

Authors:  Benjamin Small; Charles E F Millard; Edwina P Kisanga; Andreanna Burman; Anika Anam; Clare Flannery; Ayman Al-Hendy; Shannon Whirledge
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

5.  Marine and semi-synthetic hydroxysteroids as new scaffolds for pregnane X receptor modulation.

Authors:  Valentina Sepe; Francesco Saverio Di Leva; Claudio D'Amore; Carmen Festa; Simona De Marino; Barbara Renga; Maria Valeria D'Auria; Ettore Novellino; Vittorio Limongelli; Lisette D'Souza; Mahesh Majik; Angela Zampella; Stefano Fiorucci
Journal:  Mar Drugs       Date:  2014-05-27       Impact factor: 5.118

6.  Ulipristal acetate for Japanese women with symptomatic uterine fibroids: A double-blind, randomized, phase II dose-finding study.

Authors:  Minoru Irahara; Yasuhiro Maejima; Nobuhiro Shinbo; Yuji Yamauchi; Hideki Mizunuma
Journal:  Reprod Med Biol       Date:  2019-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.